Spinal Cord and Nerve Root Stimulators

Policy # 00260
Original Effective Date: 08/18/2010
Current Effective Date: 04/09/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Spinal Cord Stimulation (including burst, high frequency, and traditional stimulation methods)

Based on review of available data, the Company may consider stimulator trial to be eligible for coverage** when all of the following patient selection criteria are met:

- The patient has chronic intractable neuropathic pain of the trunk and/or limbs associated with at least ONE (1) of the following conditions:
  - Lumbosacral arachnoiditis as documented by high levels of protein in the cerebrospinal fluid and/or imaging (MRI or myelography); or
  - Nerve root injuries that are post-surgical after a spine surgery (e.g., failed back syndrome)
  - Complex regional pain syndrome (CRPS), type I or type II (formerly known as reflex sympathetic dystrophy or causalgia) which meets diagnostic criteria for CRPS as outlined in Policy Guideline Section; and
- Severe pain and disability with documented pathology or an objective basis for the pain; and
- Dorsal column stimulation is being used as a late or last resort after documented failure of at least 6 consecutive months of physician-supervised multimodal conservative management (See Policy Guideline Section); and
- Failed trial of regional sympathetic blocks in the case of CRPS; and
- There is no evidence of existing untreated drug addiction; and
- The patient has been evaluated by a pain management specialist prior to implantation; and
Spinal Cord and Nerve Root Stimulators

Policy # 00260

Original Effective Date: 08/18/2010

Current Effective Date: 04/09/2023

- All the facilities, equipment, and professional and support personnel required for the proper diagnosis, treatment training, and follow-up of the patient must be available; and
- At least one surgical opinion has been obtained to ensure that the patient does not have a surgically correctable lesion (excludes CRPS); and
- Documentation of an evaluation by a mental health provider within 6 months of a stimulator trial request (e.g., a face-to-face assessment with or without psychological questionnaires and/or psychological testing) that confirms no evidence of an inadequately controlled mental health problem (e.g., alcohol or drug dependence, depression, psychosis) that would negatively impact the success of a spinal cord stimulator or contraindicate its placement.

Stimulator Implantation (Permanent)

Based on review of available data, the Company may consider permanent stimulator implantation to be eligible for coverage** when ALL of the following criteria are met:

- The patient meets all of the criteria for a stimulator trial; and
- A stimulator trial of at least three (3) days duration has been performed; and
- Documented pain reduction and functional improvement following the stimulator trial with at least a 50% reduction of target pain or analgesic medication use, and specific evidence of improved function

Stimulator Revision or Removal

Based on review of available data, the Company may consider stimulator revision or removal to be eligible for coverage** when ANY of the following criteria are met:

- Stimulator hardware complication including
  - Lead migration
  - Infection
  - Painful generator site
- Stimulator response complications including
  - Loss of effectiveness
  - Patient intolerance
  - Development of new neurologic deficits
- Planned procedure where stimulators are contraindicated including
  - Magnetic resonance imaging (MRI)
  - Automatic implantable cardioverter defibrillator (AICD)
Dorsal Root Ganglion Stimulation
Based on review of available data, the Company may consider dorsal root ganglion (DRG) stimulation as an alternative to dorsal column stimulation in patients with moderate to severe chronic intractable pain of the lower limbs from complex regional pain syndrome (CRPS) types I or II and who otherwise meet above criteria for spinal cord stimulator trial or implantation to be **eligible for coverage.**

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers all other indications, including but not limited to the following, to be **not medically necessary:**

- Use of spinal cord stimulation for the treatment of critical limb ischemia to forestall amputation, refractory angina pectoris, heart failure, and cancer-related pain.
- Dorsal root ganglion neurostimulation for any non-CRPS lower extremity indication
- Dorsal root ganglion neurostimulation in patients with CRPS lower extremity who currently have a spinal cord stimulator or who have previously failed spinal cord stimulation therapy
- Simultaneous placement of a dorsal column and dorsal root ganglion stimulator
- Replacement of a conventional spinal cord stimulator with a burst, high frequency, or DRG stimulator in the absence of an indication for stimulator removal

Based on review of available data, the Company considers a repeat trial if the initial trial failed, unless failure was due to mechanical causes such as device failure or failure to guide the percutaneous stimulator lead to the appropriate level, to be **not medically necessary:**

Policy Guidelines
Documentation supporting medical necessity should be submitted at the time of the request and must include the following components:
Conservative management should include a combination of strategies to reduce inflammation, alleviate pain, and correct underlying dysfunction, including physical therapy AND at least one complementary conservative treatment-strategy.

- Physical therapy requirement includes ANY of the following:
  - Physical therapy rendered by a qualified provider of physical therapy services; or

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Spinal Cord and Nerve Root Stimulators

Policy # 00260
Original Effective Date: 08/18/2010
Current Effective Date: 04/09/2023

- Supervised home treatment program that includes all of the following:
  - Participation in a patient specific or tailored program
  - Initial active instruction by MD/DO/PT with redemonstration of patient ability to perform exercises
  - Compliance (documented or by clinician attestation on follow-up evaluation)
    - Exception to the physical therapy requirement in unusual circumstances (for instance, intractable pain so severe that physical therapy is not possible) when clearly documented in the medical record
- Complementary conservative treatment requirement includes ANY of the following:
  - Anti-inflammatory medications and analgesics (in the absence of contraindications)
  - Adjunctive medications such as nerve membrane stabilizers or muscle relaxants (in the absence of contraindications)
- Alternative therapies such as acupuncture, chiropractic manipulation, massage therapy, activity modification, and/or a trial period of rest (e.g., from the aggravating/contributing factors) where applicable
- Interventional modalities
  - Minimally invasive interventional pain procedures such as epidural injections, facet joint procedures, and sympathetic blocks as appropriate

Clinical reevaluation. In most cases, reevaluation should include a physical examination. Direct contact by other methods, such as telephone communication or electronic messaging, may substitute for in-person evaluation when circumstances preclude an office visit.

Failure of conservative management requires ALL of the following:
- Patient has completed a full course of conservative management (as defined above) for the current episode of care; and
- Worsening of or no significant improvement in signs and/or symptoms upon clinical reevaluation; and
- More invasive forms of therapy are being considered

Documentation of compliance with a plan of therapy that includes elements from these areas is required where conservative management is appropriate.
Spinal Cord and Nerve Root Stimulators

Policy # 00260
Original Effective Date: 08/18/2010
Current Effective Date: 04/09/2023

Reporting of symptom severity – Severity of pain and its associated impact on activities of daily living (ADLs) and instrumental ADLs (IADLs) are key factors in determining the need for intervention. For purposes of this guideline, significant pain and functional impairment refer to pain that is at least 3 out of 10 in intensity and is associated with inability to perform at least two (2) ADLs and/or IADLs.

Imaging studies -- All imaging must be performed and read by an independent radiologist. If discrepancies should arise in the interpretation of the imaging, the radiology report will supersede. The results of all imaging studies should correlate with the clinical findings in support of the requested procedure.

Diagnostic criteria for complex regional pain syndrome (CRPS) include:
- Continuing pain that is disproportionate to any inciting event
- At least ONE symptom reported in at least THREE (3) of the following categories:
  o Sensory: Hyperesthesia or allodynia
  o Vasomotor: Temperature asymmetry, skin color changes, skin color asymmetry
  o Sudomotor/edema: Edema, sweating changes, or sweating asymmetry
  o Motor/trophic: Decreased range of motion, motor dysfunction (e.g., weakness, tremor, dystonia), or trophic changes (e.g., hair, nail, skin)
- At least ONE sign at time of evaluation in at least TWO (2) of the following categories:
  o Sensory: Evidence of hyperalgesia (to pinprick), allodynia (to light touch, temperature sensation, deepsomatic pressure, or joint movement)
  o Vasomotor: Evidence of temperature asymmetry (>1°C), skin color changes or asymmetry
  o Sudomotor/edema: Evidence of edema, sweating changes, or sweating asymmetry
  o Motor/trophic: Evidence of decreased range of motion, motor dysfunction (e.g., weakness, tremor, dystonia), or trophic changes (e.g., hair, nail, skin)
  o No other diagnosis better explaining the signs and symptoms

**Background/Overview**
Spinal cord stimulators, also known as dorsal column stimulators (“stimulators”), are implantable devices used to treat chronic pain. Electrodes are surgically placed within the dura mater via
laminectomy, or by percutaneous insertion into the epidural space. Low voltage electrical signals are delivered to the dorsal column of the spinal cord in order to override or mask sensations of pain.

The patient’s pain distribution pattern determines the level at which the stimulation lead is placed. The lead may incorporate 4 to 8 electrodes, with 8 electrodes typically used for complex pain patterns, such as bilateral pain or pain extending from the limbs to the trunk.

Implantation is typically a two-step process. Initially, the electrode is temporarily implanted in the epidural space, allowing a trial period of stimulation. Once treatment effectiveness is confirmed (defined as at least 50% reduction in pain), the electrodes and radio receiver/transducer are permanently implanted.

Extensive programming of the neurostimulators is often required to achieve optimal pain control.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

A large number of neurostimulator devices have been approved by the FDA through the premarket approval process under FDA product code: LGW (stimulator, spinal-cord, totally implanted for pain relief), PMP (Dorsal Root Ganglion Stimulator for Pain Relief), and GZB (Stimulator, Spinal-Cord, Implanted [Pain Relief]) (Table 1). In October 2016, the FDA approved BurstDR™ stimulation (St. Jude Medical), a clinician programmer application that provides intermittent "burst" stimulation for patients with certain St. Jude spinal cord stimulation devices.

**Table 1. Premarket Approval Information for Spinal Cord and Dorsal Root Ganglion Stimulator Devices**

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Product code</th>
<th>Original approval date</th>
<th>Original PMA number</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Algovita SCS</td>
<td>Nuvectra Corporation</td>
<td>LGW</td>
<td>Nov 2015</td>
<td>P130028</td>
<td>Chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed</td>
</tr>
<tr>
<td>Neostimulator System</td>
<td>Manufacturer/Models</td>
<td>Approval Date</td>
<td>Code</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>---------------------</td>
<td>---------------</td>
<td>------</td>
<td>------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Axium (1st generation) and Proclaim DRG (2nd generation)</td>
<td>Abbott Medical</td>
<td>Feb 2016</td>
<td>P150004</td>
<td>Moderate to severe chronic intractable pain of the lower limbs in adult patients with Types I and II CRPS</td>
<td></td>
</tr>
<tr>
<td>Cordis Programmable Neural Stimulator Models 900a</td>
<td>Cordis Corporation</td>
<td>Apr 1981a</td>
<td>P800040</td>
<td>Stimulator, Spinal-Cord, Totally Implanted For Pain Relief</td>
<td></td>
</tr>
<tr>
<td>Freedom SCS</td>
<td>Stimwave Technologies</td>
<td>Aug 2016</td>
<td>K180981</td>
<td>Chronic, intractable pain of the trunk and/or lower limbs, including unilateral or bilateral pain</td>
<td></td>
</tr>
<tr>
<td>Genesis And Eon Family Neurostimulation (Ipg) System</td>
<td>St. Jude Medical/Abbott Medical</td>
<td>Nov 2001</td>
<td>P010032</td>
<td>Chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain</td>
<td></td>
</tr>
</tbody>
</table>
| Itrel Totally Implantable SCS                                | Medtronic Neuromodulation | Nov 1984 | P840001 | Chronic, intractable pain of the trunk and/or limbs-including unilateral or bilateral pain associated with the following conditions:  
  - Failed Back Syndrome (FBS) or low back syndrome or failed back  
  - Radicular pain syndrome or radiculopathies resulting in pain secondary to FBS or herniated disk |
### Precision SCS Systems
- **Manufacturer:** Boston Scientific Corporation
- **Model:** LGW
- **Approval Date:** Apr 2004
- **Policy Number:** P030017
- **Coverage:** Chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, Types 1 and 2 CRPS, intractable low back pain and leg pain.

### Senza SCS System
- **Manufacturer:** Nevro Corporation
- **Model:** LGW
- **Approval Date:** May 2015
- **Policy Number:** P130022
- **Coverage:** Chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain, and leg pain.

When programmed to include a frequency of 10 kHz:
- Chronic intractable pain of the lower limbs, including unilateral or bilateral pain, associated with diabetic peripheral neuropathy.
Spinal Cord and Nerve Root Stimulators

Policy # 00260
Original Effective Date: 08/18/2010
Current Effective Date: 04/09/2023

CRPS: Complex regional pain syndrome; PMA: premarket approval; SCS: spinal cord stimulation.

Withdrawn in 2016

Centers for Medicare and Medicaid Services (CMS)

According to Medicare policy, the implantation of central nervous system stimulators may be covered as therapies for the relief of chronic intractable pain, subject to the following conditions:

- The implantation of the stimulator is used only as a late resort (if not a last resort) for patients with chronic intractable pain;
- With respect to item a, other treatment modalities (pharmacological, surgical, physical, or psychological therapies) have been tried and did not prove satisfactory, or are judged to be unsuitable or contraindicated for the given patient;
- Patients have undergone careful screening, evaluation, and diagnosis by a multidisciplinary team prior to implantation (such screening must include psychological, as well as physical evaluation);
- All the facilities, equipment, and professional and support personnel required for the proper diagnosis, treatment training, and follow-up of the patient (including that required to satisfy item c) must be available; and
- Demonstration of pain relief with a temporarily implanted electrode precedes permanent implantation.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Spinal cord stimulation delivers low-voltage electrical stimulation to the dorsal columns of the spinal cord to block the sensation of pain; this is achieved through a surgically implanted spinal cord...
Spinal Cord and Nerve Root Stimulators

Policy # 00260
Original Effective Date: 08/18/2010
Current Effective Date: 04/09/2023

stimulation device, which comes equipped with a radiofrequency receiver. The neurostimulator device is also issued with a standard power source (battery) that can be implanted or worn externally. Other neurostimulators target the dorsal root ganglion.

Summary of Evidence
Treatment-Refractory Chronic Pain
For individuals who have treatment-refractory chronic pain of the trunk or limbs who receive standard spinal cord stimulation, the evidence includes systematic reviews and randomized controlled trials (RCTs). Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. Available RCTs are heterogeneous regarding underlying diagnoses in select patient populations. However, the trials including patients with underlying neuropathic pain processes have shown a significant benefit with spinal cord stimulation. Systematic reviews have supported the use of spinal cord stimulation to treat refractory trunk or limb pain, and patients who have failed all other treatment modalities have few options. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have treatment-refractory chronic pain of the trunk or limbs who receive high-frequency spinal cord stimulation, the evidence includes a systematic review and 4 RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. Two RCTs that enrolled participants not previously treated with spinal cord stimulation reported clinically and statistically significant benefits associated with high-frequency spinal cord stimulation. Another RCT in patients who had chronic pain despite previous treatment with standard spinal cord stimulation found no benefit for those receiving high-frequency stimulation compared with sham-control; however, it is difficult to compare these findings with other trials of spinal cord stimulation due to the different patient populations, short treatment periods, and the crossover period effect. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have treatment-refractory chronic pain of the trunk or limbs who receive dorsal root ganglion neurostimulation, the evidence includes a systematic review, an RCT, and case series. Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. The unblinded RCT found that patients receiving dorsal root ganglion neurostimulation had significantly higher rates of treatment success (physical functioning score and quality of life measures), at 3 and 12 months compared with those receiving standard spinal cord stimulation.
Spinal Cord and Nerve Root Stimulators

Policy #: 00260  
Original Effective Date: 08/18/2010  
Current Effective Date: 04/09/2023  

stimulation devices. Dorsal root ganglion neurostimulation was found to be noninferior to spinal cord stimulation in the percentage achieving ≥50% pain reduction, emotional functioning score, and 36-Item Short-Form Health Survey scores. Both groups experienced paresthesias but patients in the dorsal root ganglion group reported less postural variation in paresthesia and reduced extraneous stimulation in nonpainful areas. Rates of serious adverse events were similar between the 2 study arms. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

**Critical Limb Ischemia**  
For individuals who have critical limb ischemia who receive spinal cord stimulation, the evidence includes systematic reviews of several small RCTs. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, morbidity events, hospitalizations, and treatment-related morbidity. In pooled analyses, spinal cord stimulation was associated with a lower risk of amputation versus control, but results were not consistently statistically significant due to differences in methodologies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Treatment-Refractory Angina Pectoris**  
For individuals who have treatment-refractory angina pectoris who receive spinal cord stimulation, the evidence includes systematic reviews and RCTs. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, morbidity events, hospitalizations, and treatment-related morbidity. Numerous small RCTs have evaluated spinal cord stimulation as a treatment for refractory angina. While some have reported benefits, most have not. In 2 recent RCTs, there was no significant benefit in the primary outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

**Heart Failure**  
For individuals who have heart failure who receive spinal cord stimulation, the evidence includes RCTs. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, morbidity events, hospitalizations, and treatment-related morbidity. An RCT (N=66) comparing spinal cord stimulation using active stimulation with sham-control in patients who had New York Heart Association functional class III heart failure and a left ventricular ejection fraction of 35% or less did not find significant differences between groups, but might have been underpowered to do so.
Spinal Cord and Nerve Root Stimulators

Policy # 00260
Original Effective Date: 08/18/2010
Current Effective Date: 04/09/2023

The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Cancer-Related Pain
For individuals who have cancer-related pain who receive spinal cord stimulation, the evidence includes case series. Relevant outcomes are symptoms, functional outcomes, medication use, and treatment-related morbidity. No RCTs evaluating spinal cord stimulation in this population were identified. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

References

Policy History
Original Effective Date: 08/18/2010
Current Effective Date: 04/09/2023
08/05/2010 Medical Policy Committee review
08/18/2010 Medical Policy Implementation Committee approval. New Policy.
08/04/2011 Medical Policy Committee review
08/17/2011 Medical Policy Implementation Committee approval.
Spinal Cord and Nerve Root Stimulators

Policy # 00260
Original Effective Date: 08/18/2010
Current Effective Date: 04/09/2023


05/06/2021 Medical Policy Committee review
05/12/2021 Medical Policy Implementation Committee approval. No change to coverage.
12/02/2021 Medical Policy Committee review
12/08/2021 Medical Policy Implementation Committee approval. Waived surgical opinion requirement for patients with CRPS. Updated references. Allowed minimally invasive pain procedures to satisfy conservative management definition, specified timing of mental health evaluation, defined indications for repeat stimulator trial. Updated to track AIM guidelines.

12/01/2022 Medical Policy Committee review
12/07/2022 Coding update
12/14/2022 Medical Policy Implementation Committee approval. More rigorous definition of the supervised home PT requirement and removal of CBT as a conservative care modality. A repeat trial is not medically necessary if the initial trial failed, unless failure was due to mechanical causes, such as device failure or failure to guide the percutaneous stimulator lead to the appropriate level.

Next Scheduled Review Date: 12/2023

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2021 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT,
Spinal Cord and Nerve Root Stimulators

Policy # 00260
Original Effective Date: 08/18/2010
Current Effective Date: 04/09/2023

and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>63650, 63655, 63663, 63664, 63685, 63688</td>
</tr>
<tr>
<td>HCPCS</td>
<td>C1767, C1820, C1822, L8679, L8680, L8682, L8683, L8685, L8686, L8687, L8688</td>
</tr>
<tr>
<td></td>
<td>Add codes effective 01/01/2023: C1826, C1827</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);

©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Spinal Cord and Nerve Root Stimulators

Policy # 00260
Original Effective Date: 08/18/2010
Current Effective Date: 04/09/2023

2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:
   A. In accordance with nationally accepted standards of medical practice;
   B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
   C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

† Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.